Molbio Diagnostics IPO 2026: Price Band, GMP, Subscription, Financials & Key Details

The Molbio Diagnostics IPO opens for subscription on 10 August 2026 and closes on 12 August 2026. The company plans to raise funds through a Book Build Issue, comprising a fresh issue worth ₹200 crore and an Offer for Sale (OFS) of 0.92 crore equity shares. The company is yet to announce the IPO price band, total issue size, lot size, and minimum investment. The shares are proposed to be listed on both the NSE and BSE on 17 August 2026.

Molbio Diagnostics is a leading healthcare technology company specializing in point-of-care molecular diagnostics. It is widely recognized for its Truenat platform, a portable PCR-based diagnostic system capable of detecting infectious and non-communicable diseases within an hour. The company has established a strong global presence with operations in over 80 countries and serves governments, hospitals, diagnostic laboratories, and public healthcare programs.

In this article, we'll cover the Molbio Diagnostics IPO details, GMP, subscription status, financial performance, business model, strengths, risks, and whether investors should consider applying.

Molbio Diagnostics IPO Details

Molbio Diagnostics IPO Timeline

Molbio Diagnostics Financial Performance

Molbio Diagnostics has delivered strong financial growth over the last three financial years, driven by increasing adoption of its molecular diagnostic solutions across India and international markets. The company has reported healthy growth in revenue, profitability, and net worth, reflecting rising demand for its Truenat platform and recurring sales of diagnostic test kits.

Molbio Diagnostics Financial Highlights

Key Financial Ratios

The company's financials indicate consistent revenue growth, improving profitability, and healthy operating margins. Although borrowings increased during FY26 due to business expansion and capital expenditure, Molbio continues to maintain strong return ratios supported by its technology-driven business model and recurring revenue from proprietary diagnostic consumables.

Molbio Diagnostics IPO GMP

As of 4 August 2026, there is no Grey Market Premium (GMP) available for the Molbio Diagnostics IPO because the company has not yet announced the IPO price band.

Since the IPO pricing details have not been released, the estimated listing price cannot be calculated at this stage. The Grey Market Premium will begin updating once the price band is officially announced and unofficial trading starts.

Please note that GMP is an unofficial market indicator and should not be considered the sole basis for making an investment decision.

Molbio Diagnostics IPO Subscription Status

The Molbio Diagnostics IPO will open for subscription from 10 August 2026 to 12 August 2026.

Current Subscription: Yet to Open

The live subscription data will become available once bidding opens on 10 August 2026. Investors can then track subscription across Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and Retail Individual Investors (RII).

Molbio Diagnostics IPO Day-wise Subscription Trend

What is the current subscription data for Molbio Diagnostics IPO?

The current subscription data will be updated using official BSE and NSE bidding information after the IPO opens. The report will include the number of shares offered, shares bid, and bid amount across each investor category.

What is Molbio Diagnostics Ltd.?

Founded in 2000, Molbio Diagnostics Limited is an Indian healthcare technology company engaged in developing rapid molecular diagnostic solutions for infectious and non-communicable diseases. The company focuses on delivering accurate, affordable, and decentralized point-of-care (POC) diagnostic technologies, particularly for resource-limited healthcare settings.

Molbio is best known for its flagship Truenat platform, a portable real-time Polymerase Chain Reaction (PCR) system capable of delivering molecular diagnostic results within an hour. As of 31 March 2025, Truenat was patented in over 100 countries and supported testing for 30 diseases through 42 molecular assays, including Tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, HPV, and several other infectious diseases.

Notably, the Truenat TB assay is among only two World Health Organization (WHO)-endorsed rapid molecular diagnostic tests for the initial diagnosis of tuberculosis and rifampicin resistance, making it an important technology in global public healthcare.

Beyond molecular diagnostics, the company also offers radiology, digital pathology, and breast cancer screening solutions through its subsidiary Prognosys, associate OptraScan, and technology collaboration with UE Lifesciences.

Molbio operates five manufacturing facilities across Goa, Visakhapatnam, and Bengaluru, producing diagnostic instruments, test kits, portable X-ray systems, and other healthcare technologies. As of March 31, 2025, the company had installed over 10,000 diagnostic devices worldwide, serving customers in more than 80 countries through 33 international distributors.

The company follows a recurring revenue model by generating income from both diagnostic device sales and proprietary testing cartridges and consumables, providing stable long-term revenue visibility.

As of 31 March 2025, Molbio Diagnostics employed 1,000 permanent employees and 1,511 contract workers, supporting its manufacturing, research, product development, and global distribution operations.

Objects of the Molbio Diagnostics IPO

The company plans to utilize the net proceeds from the fresh issue for the following purposes:

• ₹125.12 crore towards establishing infrastructure for a new Research & Development (R&D) facility, Centre of Excellence, and related office space.
• ₹80.81 crore for purchasing plant, machinery, and equipment for Goa Unit I, Goa Unit II, and Visakhapatnam manufacturing facility.
• Remaining funds for general corporate purposes.

Competitive Strengths

• Pioneer in point-of-care molecular diagnostics with the globally recognized Truenat PCR platform.
• Truenat is patented in 100+ countries and supports testing for 30 diseases through 42 diagnostic assays.
• One of only two WHO-endorsed rapid molecular diagnostic platforms for Tuberculosis diagnosis and rifampicin resistance detection.
• Strong recurring revenue model driven by proprietary diagnostic cartridges and consumables.
• Global presence across 80+ countries with an established international distributor network.
• Multiple manufacturing facilities and strong in-house research & development capabilities.
• Diversified healthcare portfolio spanning molecular diagnostics, radiology, digital pathology, and breast cancer screening.
• Healthy financial performance supported by increasing adoption of molecular diagnostic technologies.

Risks Investors Should Consider

• The company derives a significant portion of its revenue from government healthcare programs and institutional customers.
• Rapid technological advancements require continuous investment in research and product innovation.
• Regulatory approvals and compliance requirements across multiple countries may impact product launches.
• High dependence on proprietary technology and intellectual property.
• Growing competition from global diagnostic and medical technology companies.
• Any disruption in manufacturing or supply chain operations could impact production and revenue.
• International business exposes the company to foreign exchange fluctuations and geopolitical risks.

Should You Invest in Molbio Diagnostics IPO?

Molbio Diagnostics Limited operates in one of the fastest-growing segments of the healthcare industry, offering innovative molecular diagnostic solutions for infectious and non-communicable diseases. Its flagship Truenat platform has gained global recognition for providing rapid, accurate, and portable PCR-based testing, making it particularly valuable in decentralized and resource-limited healthcare settings. The company has also diversified into radiology, digital pathology, and breast health screening, expanding its presence across multiple healthcare technology segments.

Financially, Molbio has demonstrated strong growth over the past three years, reporting higher revenue, improving profitability, and healthy operating margins. Its recurring revenue model from proprietary diagnostic test kits, combined with a growing installed base of diagnostic devices across more than 80 countries, provides long-term revenue visibility. The IPO proceeds will primarily be utilized to strengthen research and development capabilities and expand manufacturing infrastructure, supporting future business growth.

However, investors should also consider factors such as dependence on government healthcare programs, continuous research and development expenditure, regulatory approvals, increasing competition from global diagnostic companies, and execution risks associated with expansion. Since the IPO price band and Grey Market Premium (GMP) have not yet been announced, investors should monitor the latest developments, valuation, and subscription response before making an investment decision.

Looking to Invest in Molbio Diagnostics Before Its IPO?

If you want to invest in Molbio Diagnostics before its public listing, you can check the latest unlisted share price, valuation, availability, and investment process on UnlistedKraft's dedicated page once the shares become available in the unlisted market.

Summary

The Molbio Diagnostics IPO is a Mainboard Book Build Issue comprising a fresh issue of ₹200 crore and an Offer for Sale (OFS) of 0.92 crore equity shares. The company plans to utilize the fresh issue proceeds primarily to establish a new research and development facility, expand manufacturing capabilities, and support future business growth.

Molbio Diagnostics has built a strong position in the global molecular diagnostics market through its innovative Truenat PCR platform, diversified healthcare technology portfolio, and presence across more than 80 countries. Supported by consistent financial growth, recurring revenue streams, and increasing adoption of rapid diagnostic solutions, the company is well-positioned to benefit from rising healthcare demand. Investors should keep track of the price band, GMP, subscription status, and valuation before making an investment decision.

Frequently Asked Questions (FAQs)

What is the Molbio Diagnostics IPO?

Molbio Diagnostics IPO is a Mainboard Book Build Issue comprising a fresh issue of ₹200 crore and an Offer for Sale (OFS) of 0.92 crore equity shares.

What are the Molbio Diagnostics IPO dates?

The IPO will open on 10 August 2026 and close on 12 August 2026.

What is the Molbio Diagnostics IPO price band?

The price band has not yet been announced by the company. It is expected to be released before the IPO opens for subscription.

What is the lot size of Molbio Diagnostics IPO?

The lot size and minimum investment amount have not yet been announced.

What is the Molbio Diagnostics IPO GMP today?

As of 4 August 2026, there is no Grey Market Premium (GMP) available because the IPO price band has not yet been declared. The GMP will be updated once unofficial market trading begins.

When will Molbio Diagnostics IPO allotment take place?

The tentative basis of allotment is scheduled for 13 August 2026.

When is Molbio Diagnostics IPO listing?

The shares are expected to be listed on BSE and NSE on 17 August 2026.

Sources

• Molbio Diagnostics DRHP
• Chittorgarh IPO
• InvestorGain
• InvestKraft

Disclaimer

This article is intended for informational and educational purposes only and should not be considered financial or investment advice. IPO details, Grey Market Premium (GMP), subscription figures, issue size, allotment dates, and listing timelines are subject to change. Investors should carefully read the Red Herring Prospectus (RHP), verify the latest updates from official sources, and consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks.

Author: Komal Bhatt

Komal Bhatt is a finance content writer at InvestKraft, specialising in well-researched articles on financial products, stock markets, and investment opportunities, with a particular focus on unlisted shares.

She holds a Master’s degree in Commerce from the University of Delhi, which gives her a solid academic foundation in finance and business. With over three years of hands-on experience in creating digital finance content, Komal has developed a clear understanding of investor needs through her work on wealth management, NISM certification programs, and market education materials.

Komal is passionate when it comes to breaking down complex financial concepts into simple, accurate and actionable insights. Her goal is to help everyday investors understand markets better and make more informed decisions based on reliable, research-backed information.